A Fusion Protein of Derp2 Allergen and Flagellin Suppresses Experimental Allergic Asthma

Area of Science:

• Immunology
• Allergology
• Biotechnology

Background:

• House dust mite (HDM) allergens are major triggers for allergic rhinitis and asthma.
• Previous research showed *Vibrio vulnificus* flagellin B (FlaB) combined with allergens can improve lung function and reduce airway inflammation via Toll-like receptor 5 signaling.
• This study investigates a new therapeutic approach by fusing a key HDM allergen, Derp2, with FlaB.

Purpose of the Study:

• To compare the therapeutic efficacy of a Derp2-FlaB fusion protein against a mixture of Derp2 and FlaB.
• To evaluate the anti-asthma immunomodulatory capacity of the Derp2-FlaB fusion protein in a Derp2-induced mouse asthma model.

Main Methods:

• BALB/c mice were sensitized with Derp2 and HDM.
• Mice received treatments of Derp2 alone, a Derp2 + FlaB mixture, or the Derp2-FlaB fusion protein.
• Airway responses and immune responses were assessed after intranasal challenge with Derp2.

Main Results:

• The Derp2-FlaB fusion protein demonstrated superior efficacy compared to the Derp2 + FlaB mixture.
• Significant reductions were observed in airway hyperresponsiveness, lung eosinophil infiltration, and Derp2-specific IgE levels with the fusion protein.
• The fusion protein effectively inhibited Th2 responses, indicating strong anti-asthma immunomodulatory effects.

Conclusions:

• The Derp2-FlaB fusion protein exhibits significant anti-asthma properties by preventing airway inflammation in a murine model.
• This fusion protein shows promise as a vaccine candidate for therapeutic intervention in HDM-mediated allergic asthma.
• Targeting Th2 responses is a key mechanism for the observed therapeutic benefits.